The San Francisco Bay Area has experienced a particularly intense HIV epidemic, with men who have sex with men (MSM), Black, and Latino populations most heavily impacted in the region. Drs. Susan Buchbinder and Diane Havlir are scientific leaders in HIV prevention and treatment, respectively. Together they will form the San Francisco Bay Area Clinical Trials Unit (SFBay CTU), affiliated with the HVTN, HPTN, MTN, and ACTG. This integrated research organization will accomplish 3 specific aims through these Networks: 1) advance prevention and treatment science and their intersection through scientific leadership; 2) implement clinical trials efficiently and with excellent adherence to protocol while engaging diverse communities; and 3) develop a new generation of diverse leaders in HIV prevention and treatment science. Drs. Buchbinder and Havlir are joined by a diverse pool of talented investigators who have provided leadership across the Networks, serving on numerous scientific leadership committees and working groups and chairing a range of prevention and treatment protocols. The 3 Clinical Research Sites (Bridge HIV led by Buchbinder, UCSF led by Havlir, and Stanford led by Zolopa) all have a record of excellence in enrollment, retention, and adherence to protocol requirements, and actively engage local communities in their research.
The newly formed San Francisco Bay Clinical Trials Unit will conduct HIV vaccine, prevention and treatment trials in San Francisco, Oakland, San Jose, and their surrounding communities. By bringing together leading scientists and a diverse community in the San Francisco Bay Area, this new research unit will develop ways to prevent and treat HIV infections and work towards an effective HIV vaccine and cure.
|Wilson, Erin C; Jalil, Emilia M; Castro, Cristiane et al. (2018) Barriers and facilitators to PrEP for transwomen in Brazil. Glob Public Health :1-9|
|Angelidou, Konstantia; Hunt, Peter W; Landay, Alan L et al. (2018) Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy. J Infect Dis 218:239-248|
|Giguere, Rebecca; Rael, Christine Tagliaferri; Sheinfil, Alan et al. (2018) Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS Behav 22:388-401|
|Hughes, Shana D; Sheon, Nicolas; Andrew, Erin V W et al. (2018) Body/Selves and Beyond: Men's Narratives of Sexual Behavior on PrEP. Med Anthropol 37:387-400|
|Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912|
|Scheer, Susan; Hsu, Ling; Schwarcz, Sandra et al. (2018) Trends in the San Francisco Human Immunodeficiency Virus Epidemic in the ""Getting to Zero"" Era. Clin Infect Dis 66:1027-1034|
|Glidden, David V; Mulligan, Kathleen; McMahan, Vanessa et al. (2018) Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clin Infect Dis 67:411-419|
|Fuchs, Jonathan D; Stojanovski, Kristefer; Vittinghoff, Eric et al. (2018) A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis. AIDS Patient Care STDS 32:104-111|
|Ramsuran, Veron; Naranbhai, Vivek; Horowitz, Amir et al. (2018) Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science 359:86-90|
|Jalil, Emilia M; Grinsztejn, Beatriz; Velasque, Luciane et al. (2018) Awareness, Willingness, and PrEP Eligibility Among Transgender Women in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr 79:445-452|
Showing the most recent 10 out of 130 publications